UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 11, 2014
AMARANTUS BIOSCIENCE HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
Nevada | 333-148922 | 26-0690857 |
(State or other jurisdiction of incorporation or organization) | (Commission File Number) |
IRS Employer Identification No.) |
655 Montgomery Street Suite 900 San Francisco, CA |
94111 |
(Address of Principal Executive Offices) | (Zip Code) |
(408) 737-2734
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 |
Other Events
On December 11, 2014, Amarantus Bioscience Holdings, Inc. (the “Company”) issued a press release appointing Elise Brownell, Ph.D., as Senior Vice President of Operations and Project Management. The press release is attached as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference. |
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. | Description | |
99.1 | Press Release dated December 11, 2014 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
AMARANTUS BIOSCIENCE HOLDINGS, INC. | ||||
Date: December 11, 2014 | By: | /s/ Gerald E. Commissiong | ||
Name: Gerald E. Commissiong | ||||
Title: Chief Executive Officer |